In February 1979 Hyland learnt of Behringwerke beginning clinical trials in 1978 in Germany on "Factor VIII Behringwerke" via a report to their head office, later confirmed by another Hyland employee.
Chronology Information
Date:
Chapter/issue
Blood Products and Addressing Risk: Viral Inactivation